Tongmai Yangxin intervening in myocardial remodeling after PCI for coronary heart disease: study protocol for a double-blind, randomized controlled trial
Open Access
- 20 March 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Trials
- Vol. 21 (1), 1-8
- https://doi.org/10.1186/s13063-020-4208-4
Abstract
Coronary heart disease (CHD) has become a common cardiovascular disease that seriously threatens the health of people. As reperfusion in the early phase and drug therapy, especially percutaneous coronary intervention (PCI), have become widely used in the clinic, the mortality of acute myocardial infarction in the short term has been reduced significantly. In addition, in 40%–56% of patients who experience myocardial infarction, cardiac dysfunction occurs and about 25%–33% develop heart failure. This study was designed as a multicenter, double-blind, randomized, placebo-controlled, parallel-group, superiority trial. Participants were randomly assigned in a 1:1 ratio through a centrally controlled, computer-generated, simple randomization schedule. The primary outcome was left ventricular end-diastolic volume index = left ventricular end-diastolic volume/body surface area. The combined secondary outcomes include traditional Chinese medicine syndrome score, echocardiogram results, 6-minute walk test results, Seattle Angina Questionnaire score, cardiac magnetic resonance imaging results, biological indicators, dynamic electrocardiogram results, and experiment event rate. Assessments will be performed at baseline and at 4, 8, and 12 weeks after randomization. This trial will demonstrate that the addition of a Tongmai Yangxin pill (TMYX) to conventional treatment will intervene in the development of cardiac remodeling and cardiac dysfunction. This study was registered in the Chinese Clinical Trial Registry on 7 May 2019. The registration number is ChiCRT1900023023 (http://www.chictr.org.cn/showproj.aspx?proj=12370).Keywords
Funding Information
- Ministry of Science and Technology (2018YFC1707402)
- Ministry of Science and Technology (No. 2019YFC1710000)
- Tianjin Zhongxin Pharmaceutical Group Co., Ltd.; Le Ren Tang Pharmaceutical Factory (No.2018YFC1707402)
This publication has 19 references indexed in Scilit:
- Analysis of bioactive components and pharmacokinetic study of herb–herb interactions in the traditional Chinese patent medicine Tongmai Yangxin PillJournal of Pharmaceutical and Biomedical Analysis, 2016
- Cardiac Remodeling: Concepts, Clinical Impact, Pathophysiological Mechanisms and Pharmacologic TreatmentArquivos Brasileiros de Cardiologia, 2016
- Rapid identification of anti-inflammatory compounds from Tongmai Yangxin Pills by liquid chromatography with high-resolution mass spectrometry and chemometric analysisJournal of Separation Science, 2015
- Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular ImagingEuropean Heart Journal – Cardiovascular Imaging, 2015
- Appropriateness criteria for cardiovascular imaging use in heart failure: report of literature reviewEuropean Heart Journal – Cardiovascular Imaging, 2014
- The Utility of Galectin-3 for Predicting Cause-Specific Death in Hospitalized Patients With Heart FailureJournal of Cardiac Failure, 2014
- Myocardial T1 mapping and extracellular volume quantification: a Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of the European Society of Cardiology consensus statementJournal of Cardiovascular Magnetic Resonance, 2013
- Heart Failure After Myocardial Infarction: Clinical Implications and TreatmentClinical Cardiology, 2011
- Heart Disease and Stroke Statistics-2010 Update A Report From the American Heart AssociationCirculation, 2010
- EPIDEMIOLOGY OF HEARY FAILURECardiology Clinics, 2001